Kai Wang

OrigiMed, Inc.

Shanghai

China

SCHOLARLY PAPERS

2

DOWNLOADS

197

SSRN CITATIONS

3

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

Axitinib in Combination with Toripalimab, a Humanized IgG4 mAb Against Programmed Death-1 (PD-1) in Patients with Metastatic Mucosal Melanoma: A Non-Randomized, Open-Label, Dose-Finding, and Cohort-Expansion Phase 1b Trial

Number of pages: 148 Posted: 24 Jan 2019
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Harvard University - Harvard Medical School and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 111 (454,814)
Citation 1

Abstract:

Loading...

Mucosal, Melanoma, anti-PD-1 antibody, Axitinib

2.

Lenvatinib Plus PD-1 Blockade in Refractory or Unresectable Biliary Tract Carcinoma: Insights from Real-World Evidences

Number of pages: 30 Posted: 08 Jul 2019
Chinese Academy of Medical Sciences - Department of Liver Surgery, Chinese Academy of Medical Sciences - Department of Hepatobiliary Surgery, OrigiMed, Inc., Chinese Academy of Medical Sciences - Department of Hepatobiliary Surgery, Chinese Academy of Medical Sciences - Department of Liver Surgery, Chinese Academy of Medical Sciences - Department of Liver Surgery, Chinese Academy of Medical Sciences - Department of Liver Surgery, Chinese Academy of Medical Sciences - Department of Liver Surgery, Chinese Academy of Medical Sciences - Department of Hepatobiliary Surgery, Chinese Academy of Medical Sciences - Department of Hepatobiliary Surgery, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Chinese Academy of Medical Sciences - Peking Union Medical College Hospital, Chinese Academy of Medical Sciences - Peking Union Medical College Hospital, Chinese Academy of Medical Sciences - Peking Union Medical College Hospital, Chinese Academy of Medical Sciences - Peking Union Medical College Hospital, Harvard University - Beth Israel Deaconess Medical Center, OrigiMed, Inc., Chinese Academy of Medical Sciences - Department of Liver Surgery, Chinese Academy of Medical Sciences - Department of Hepatobiliary Surgery, Harvard University - Beth Israel Deaconess Medical Center, OrigiMed, Inc. and Chinese Academy of Medical Sciences - Department of Liver Surgery
Downloads 86 (539,013)

Abstract:

Loading...

biliary tract cancer; lenvatinib; nivolumab; pembrolizumab; combined immunotherapy